Venture Capital

Latest Headlines

Latest Headlines

Catabasis nails $32.4M for triglyceride-busting drug

Cambridge, MA's Catabasis Pharmaceuticals has landed a $32.4 million Series B to advance its triglyceride-fighting drug, setting sights on a swelling market with a compound the company believes can outperform its competitors.

GeNO, uniQure look to leap through biotech IPO window in Q4 rush

Waltham, MA-based GeNO is looking to raise $50 million to back its work on a new, patient-friendly approach for delivering inhaled nitric oxide on the go. And a Dutch biotech, uniQure, is also positioning itself to go public after pioneering the world's first approved gene therapy.

Liquidia spins out new biotech with $25M A round

Liquidia Technologies has spun out a new biotech company in Research Triangle Park, NC, which boasts an early-stage ophthalmology program and $25 million in venture backing from some high-profile investors. 

Rare-disease specialist Ultragenyx fires off a fast $86M IPO

Back in September, when Ultragenyx CEO Emil Kakkis was talking to FierceBiotech about the company for our annual Fierce 15 report, the biotech chief confidently predicted that he could take the company public next year.

Sangart goes MIA after burning through $260M-plus on R&D

San Diego-based Sangart has gone missing in action after apparently burning through more than a quarter-billion dollars of Leucadia National cash.

ImmunGene nails $9M for armed-antibody lymphoma drug

ImmunGene is working to get its lead armed-antibody cancer treatment from the lab to the clinic, and now the California company has $9 million in Series A cash to light the way.

Therapeutic vaccine upstart Hookipa snags $27M round to fund PhI move

A pair of prominent pharma players are partnering up with a few marquee European VCs to back an up-and-coming immunotherapy biotech based in Vienna.

UPDATED: VC OrbiMed hauls in $735M fund in 'vibrant' time for biotech

As biotech venture funding plods along at a middling pace, A-list investor OrbiMed has bagged $735 million for its 5th fund, cash earmarked for life sciences companies across all stages of development.

NovaQuest lands $459M fund for goal-line dealmaking

Biopharma backer NovaQuest has closed a $459 million fund, cash the company will use to push promising, late-stage projects toward commercialization.

Fidelity bankrolls gene therapy startup with sights on hemophilia

Fidelity Biosciences is placing a big bet on gene therapy, funding the launch of startup Dimension Therapeutics with some licensed patents and a plan to develop novel treatments for hemophilia.